Miradx - Model ImuDx -Cancer Systemic Therapy Germ-Line Genetic Markers
Although it is completely logical that inherited, germ-line genetic differences, present in all cells, including those of the immune system, will predict response and toxicity to developing immune therapies, there has been little study of the genomic areas studied by MiraDx to find such biomarkers. MiraDx discovered a panel of such mutations that predict both response and toxicity to anti-PD1 and anti-PDL1 therapies currently on the market. We are working with potential partners to incorporate these findings into the newer agents to allow better patients selection to achieve improved response and less toxicity from these exciting new therapies. We are additionally working with partners to apply these mutations to all classes of developing immunotherapies.
In addition, we are currently offering the panel to predict toxicity, ImuDx, to physicians interested in this information for better managing their patients. If you would like to join our studies on ImuDx, please contact us.
Head and Neck Squamous Cell Carcinoma
Studies have definitively shown that KRAS-variant head and neck cancer patients respond differently to targeted agents used in standard treatment. Specifically, Cetuximab is an excellent choice for treatment. We are currently working towards additional collaborative studies to better define the time course and dosing, to make this the standard of care for these patients.
Non-Small Cell Lung Cancer
Physicians and researchers at MDACC and Yale University have evaluated the association between treatment response for NSCLC patients in the BATTLE trials and the KRAS-variant. Results from these studies suggest that KRAS-variant patients respond to certain drugs, such as Sorafenib, and not others, such as Gefitinib, used in metastatic lung cancer.
Ovarian Cancer
Studies show that standard treatment consisting of Platinum compounds work poorly for ovarian cancer patients with the KRAS-variant. We hope to define the best strategy for these patients, as the KRAS-variant is found in 1 of 4 newly diagnosed ovarian cancer patients.